Construction Of A Quality Control System For Ultrasound-Guided Breast Biopsy

https://www.mayoclinic.org/tests-procedures/breast-biopsy/about/pac-20384812

As an invasive procedure, ultrasound-guided breast biopsy must be performed within a strict quality control framework to maximize patient safety and diagnostic reliability. Establishing a comprehensive quality control system is a mandatory course for standardized management in medical institutions.

Personnel qualifications are the first line of defense. Physicians performing ultrasound-guided breast biopsies should possess dual qualifications in ultrasound diagnosis and interventional procedures, and regularly participate in specialized training and skills assessments. Nursing staff and pathology technicians also need to receive relevant job training to ensure seamless coordination across all stages.

Equipment and consumable management is equally crucial. Ultrasound equipment must be calibrated regularly to ensure image clarity and measurement accuracy; consumables such as puncture needles must be procured from legitimate channels, with strict adherence to warehousing and acceptance procedures to prevent counterfeit and substandard products. Disposable puncture needles must not be reused; reusable instruments must be cleaned, disinfected, and sterilized according to regulations. Before an ultrasound-guided breast biopsy, the operator should recheck the integrity and expiration date of the needle packaging.

Standardized operating procedures are the core of quality control. Medical institutions should develop detailed SOPs (Standard Operating Procedures) that clearly define indications, contraindications, operating steps, and emergency response plans. For example, for patients with abnormal coagulation function, risks must be assessed and procedures performed with caution; the needle tip position must be monitored in real time during the puncture to avoid accidental injury to the pleura or major blood vessels in the chest wall. Every ultrasound-guided breast biopsy should be fully documented, including lesion description, number of punctures, specimen quantity, and patient response, for traceability and analysis.

A complication monitoring and reporting mechanism is indispensable. Common complications such as local hematoma, infection, and pneumothorax should have clear identification criteria and management procedures. In the event of a serious adverse event, it must be reported promptly according to regulations, and a multidisciplinary discussion should be organized to find the root cause and continuously improve the procedure.

Communication between pathologists and clinicians is also a crucial aspect of quality control. The pathology department should process specimens as quickly as possible upon receipt and maintain communication with clinicians, especially when specimen quantity is insufficient or the diagnosis is uncertain. Timely feedback should be provided, and repeat biopsies should be recommended if necessary. Regular MDT (multidisciplinary team) meetings should be held to review typical cases and continuously optimize the overall quality of ultrasound-guided breast biopsy.

Only by integrating quality control awareness into every detail can we truly safeguard patient safety and maximize the value of this technology.